Antidepressant ‘shrooms: rebranding psilocybin as medication
Sixtine Fleury is a second-year graduate student in the Nautiyal Lab at Dartmouth College (NH, USA). At this year’s meeting of the Society for Neuroscience (SfN; 12–16 November; San Diego, CA, USA), she presented a poster on altered consciousness and the role of the non-hallucinatory serotonin 1B receptor in psilocybin’s therapeutic effects. We had the chance to chat to her about her poster and her experience at SfN. What were some of the key takeaways from your poster presentation? One of the key takeaways is that the serotonin 1B receptor seems to be involved in the therapeutic effects of psilocybin...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
